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Fig 1. Post-EVAR survival.
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abdominal aortic aneurysm (AAA) were identiﬁed from the American Col-
lege of Surgeons National Surgical Quality Improvement Program 2005-
2011 database. Univariable and multivariable logistic regression analyses
were performed.
Results: An iliac conduit was used in 231 patients (1.6%), while the
remainder had a femoral exposure/percutaneous EVAR. Females
comprised 32% of patients with iliac conduits in contrast to 17% of those
without (P < .0001). Patients with iliac conduits were older and had a lower
body mass index (P < .05). On univariable analysis, patients with iliac con-
duits had a higher incidence of postoperative pneumonia (3.0% vs 1.1%; P ¼
.01), ventilator dependence (4.8% vs 1.0%; P < .0001), renal failure (3.0% vs
0.7%; P < .0001), myocardial infarction (3.9% vs 0.8%; P < .0001), urinary
tract infections (3.5% vs 1.6%; P ¼ .03), peripheral nerve deﬁciency (1.3% vs
0.1%; P ¼ .004), transfusion of >4 units of red blood cells during hospital
stay (17.3% vs 4.8%; P < .0001), return to operating room (9.1% vs 3.7%; P
< .0001), and death (3.0% vs 0.9%; P ¼ .001). On multivariable logistic
regression, after controlling for comorbidities and demographics, use of
an iliac conduit was not signiﬁcantly associated (P > .05) with 30-day mor-
tality or any postoperative complication other than myocardial infarction
(odds ratio, 2.6; 95% conﬁdence interval, 1.2-5.6) and peripheral nerve deﬁ-
ciency (odds ratio, 5.1; 95% conﬁdence interval, 1.2-22.2).
Conclusions: Patients with iliac conduits for EVAR have higher post-
operative morbidity and mortality. For patients with complex iliac disease,
this is a viable alternative to allow EVAR to be performed.
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Objectives: Although the EVAR-2 trial demonstrated no beneﬁt of
endovascular abdominal aortic aneurysm (AAA) repair (EVAR) in high-
risk (HR) patients, EVAR is still performed widely in this patient cohort.
This study compared the midterm outcomes after EVAR in the HR patients
with normal-risk (NR) patients. In turn, these data were compared with the
EVAR-2 data.
Methods: A retrospective review from January 2006 to December
2013 identiﬁed 247 patients (75 HR [30.4%], 172 NR [69.6%]) who un-
derwent elective EVAR for infrarenal AAA in an academic institution and
its afﬁliated Veterans Administration hospital. The same HR criteria used
in the EVAR-2 trial were used. Overall survival, graft-related complications,
and reinterventions were estimated by the Kaplan-Meier method. HR pa-
tient’s outcomes were compared with the EVAR-2 data.Fig 2. Post-EVAR intervention-free survival.Table. Baseline characteristics
Variable
Groups
P value
(NR vs HR) EVAR-2NR HR
Age, mean (SD) years 72.4 (8.4) 71.4 (8.1) .4 76.4 (6.7)
Male sex, % 91 93 .6 85
Baseline creatinine,
mean (SD)
1.1 (0.3) 1.8 (2.3) .01 1.9 (0.3)
Cardiac disease, % 47 79 <.01 67
COPD, % 21 35 .02 N/A
Current cancer Rx, % 0 29 <.01 N/A
Statin, % 72 83 .2 39
Aspirin, % 66 63 .6 58
b-Blocker, % 60 71 .2 N/A
COPD, Chronic obstructive pulmonary disease; HR, high risk; NR, normal
risk; SD, standard deviation.Results: Baseline characteristics are detailed in the Table. Use of
aspirin (63% HR vs 66% NR; P ¼ .6), statin (83% HR vs 72% NR; P
¼ .2), and b-blockers (71% HR vs 60% NR; P ¼ .2) was similar; in the
EVAR-2 trial, the corresponding use of these medications was 58%,
39%, and not available, respectively (Table). Perioperative mortality
(0% HR vs 1.2% LR; P ¼ 1.0) and early complication rates (4% HR
vs 6% LR; P ¼ .8) were similar. In contrast, perioperative mortalityin the EVAR-2 trial was 9%. At a mean follow-up of 3 years, the inci-
dence of reintervention for AAA- or graft-related complications was
7% for HR and 10% for NR patients (P ¼ .5). The 1-, 2- and 4-
year survival in HR (85%, 77%, 65%) was lower than in NR (97%,
97%, 93%; P < .001; Fig 1), but this was more favorable compared
with a 4-year survival of 36% in the EVAR-2 trial. No difference
was seen in long-term reintervention-free survival in HR and NR (P
¼ .8; Fig 2). No late AAA ruptures occurred.
Conclusions: EVAR in HR patients can be performed with excel-
lent early survival and midterm durability results. Although HR pa-
tients have inferior overall survival compared with NR patients, our
data indicate more favorable outcomes compared with the EVAR-2
trial in terms of early mortality and longer-term survival. This may
be, in part, attributable to increased statin use. Therefore, EVAR
may be a feasible treatment option for AAA in HR patients, especially
when coupled with statin use.
Author Disclosures: S. Lim: None; P. M. Halandras: None; Y. Lee:
None; T. Park: None; P. Crisostomo: None; R. C. Hershberger:
None; B. Aulivola: None; J. S. Cho: None.
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Volume 60, Number 4 Abstracts 1107Objectives: Mechanical assist devices have assumed an increasingly
important role in the management of high-risk cardiac patients. The Impella
LP 2.5, the ﬁrst percutaneous left ventricular assist device (LVAD), is placed
in the left ventricle under ﬂuoroscopic guidance via a 13F sheath. The low
cardiac output, large sheath size, and frequent presence of peripheral artery
disease in these patients increases the risk of vascular complications (VCs)
with this device. This study was undertaken to deﬁne the incidence of
VCs and assess their effect on patient outcome.
Methods: Between July 2010 and December 2013, an Impella
LVAD device was placed in 94 patients at our institution. Patient demo-
graphics, comorbidities, complications, and 30-day mortality were
reviewed.
Results: Mean age was 67 years (range, 17-97 years), 58% were
male, 69% had a history of hypertension, 39% were diabetic, 76% had
hyperlipidemia, 55% had a history of tobacco abuse, and 65% had renal
insufﬁciency (glomerular ﬁltration rate <60 mL/min/1.73 m2). The me-
dian preprocedure cardiac ejection fraction was 30%. The majority of
cases (80) were pericoronary artery intervention. The procedure was per-
formed emergently in 54 patients. The average duration of Impella sup-
port was 1 day (range, 1-5 days). Fifteen patients (17%) had at least one
VC. Of the 11 patients with acute limb ischemia, three improved after
LVAD removal, six required open or endoluminal repair with limb
salvage in ﬁve, and two required primary above-knee amputation. Other
VCs included groin hematoma in three patients and one pseudoaneur-
ysm. Patients with a VC had a longer length of stay (average 22 days
vs 10 days for those without a VC; P ¼ .014). Thirty-day mortality
was 44% (53% in those with VC and 43% in those without; P ¼ .43).
Care was withdrawn in 18 patients (19%) or they were sent to hospice.
There was an increased incidence of care withdrawal and hospice (40% vs
15%; P ¼ .021) in patients with a VC.
Conclusions: VCs are not uncommon with placement of percuta-
neous LVADs (17%). More importantly, their occurrence is associated
with increased length of stay and acceptance of end-of-life measures in
this high-risk population.
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Long-Term Results of Intentional Celiac Artery Coverage During
Endovascular Thoracic Aortic Aneurysm Repair
Melanie Rose, MD, Benjamin Pearce, MD, Marc Passman, MD, Thomas
Matthews, MD, Mark Patterson, MD, William Jordan, MD. Vascular and
Endovascular Therapy, UAB, Birmingham, Ala
Objectives: Coverage of the celiac artery (CA) during thoracic
endovascular aortic repair (TEVAR) to provide an adequate distal sealing
zone has been described, but only preliminary results have been reported.
We aim to show the long-term outcome for celiac coverage during
TEVAR.
Methods: Patients undergoing TEVAR with coverage of the CA
origin from 2005 to 2013 were identiﬁed and retrospectively analyzed.
End points included indications for covering the CA, demonstration of
collateral circulation between the CA and the superior mesenteric artery
(SMA), anatomic features of the distal landing zone, rate of delayed reinter-
vention, technical success, presence of long-term clinical ischemic symptoms
after the procedure, and mortality.
Results: During the 8-year period, 366 patients underwent TEVAR,
18 (5%) of which had CA coverage. Indications included thoracic aneu-
rysm (11 of 18), thoracic dissection (three of 18); and type Ib endoleak
after prior TEVAR requiring extension stent graft (four of 18). At the
conclusion of the indicated procedure, 11% (two of 18) had a type Ib
endoleak related to inadequate sealing at the SMA origin and 11% (two
of 18) had a type Ia endoleak. Three of these four type I endoleaks
required reintervention, one of which was an elective secondary conversion
to open repair 2 months later. One patient (5.5%) had immediate transient
abdominal pain with transaminase elevation that resolved without interven-
tion. A second patient developed ischemic symptoms when the endograft
migrated over the SMA origin, but this was successfully treated with an
SMA stent. Other postoperative complications included spinal cord
ischemia in two patients (11%), both of which resolved prior to discharge
with one requiring intervention in the form of spinal drainage, cerebrovas-
cular event in one (5.5%), and death in one (5.5%). No additional patient
developed weight loss, postprandial pain, or computed tomography evi-
dence of bowel ischemia during surveillance up to 78 months (mean, 37
months).
Conclusions: This long-term series supports the suitability in selected
patients of covering the CA for extending distal landing zone to the visceral
aorta above the SMA. Delayed visceral ischemic symptoms are uncommon,
and the collateral ﬂow to the CA appears to be stable over time.Author Disclosures: M. Rose: None; B. Pearce: None; M. Passman:
None; T. Matthews: None; M. Patterson: None; W. Jordan: None.
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Objectives: Degenerative hepatic artery aneurysms (HAAs) are an un-
common pathology. The aim of this study was to evaluate the approach and
outcomes in operative management of HAAs with open techniques (OTs)
and endovascular techniques (ETs).
Methods: Nineteen patients who underwent intervention for an HAA
from January 1992 to March 2014 were retrospectively reviewed. Primary
outcomes included morbidity and mortality of interventions for OTs and
ETs. Secondary outcomes included long-term survival, patency, and need
for reintervention.
Results: Fourteen (74%) patients were male, with a mean age of 65
years (range, 30-80 years), including six (32%) patients with connective tissue
disorders and one (5%) with syphilitic arteritis. Most patients (58%) had syn-
chronous aneurysms elsewhere. Mean HAA size was 42 6 22 mm (11 com-
mon hepatic, 5 common and proper hepatic, 1 accessory left hepatic, and 2
right hepatic). Right upper quadrant pain was the most common symptom
(37%), followed by transaminitis (5%) and obstructive jaundice (5%). Four
patients (21%) presented ruptured. The OT was bypass in 14 patients with
HAA involving the common hepatic (n ¼ 15) and the right hepatic (n ¼
1) arteries (seven with great saphenous vein graft, six with Dacron, one
with polytetraﬂuoroethylene), aneurysmorrhaphy alone, and patch repair in
one each. Postoperative complications occurred in ﬁve patients (26%)
including hemorrhage in two, graft thrombosis in two (re-explored in
one), and common bile duct stricture that required reoperation in one. ET
of coil embolization was performed electively in three patients (two limited
to the common and one to the right hepatic arteries) without sequelae. Over-
all mortality was 16% (5% undergoing elective surgical repair vs and 50% for
ruptured repair). Mean follow-up was 34 6 46 months. Overall survival was
84% at 5 years. Primary and secondary graft patency was 86% at 5 years. One
further graft occluded at 10 years and was not intervened upon.
Conclusions: Open repair remains the mainstay treatment for degen-
erative HAA repairs to preserve arterial ﬂow to the liver. However, coil
embolization may be applied safely in select patients with aneurysms not
involving the proper hepatic artery.
Author Disclosures: Y. Erben: None; R. De Martino: None; H.
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Objectives: Calf veins are not visualized in up to 35% of lower ex-
tremity venous duplex ultrasound (DUS) scans. Little is known about the
clinical implications of nonvisualized calf veins. We sought to investigate
the incidence of nonvisualized calf veins, rate of subsequent venous throm-
boembolism (VTE), and factors inﬂuencing successful visualization on sub-
sequent DUS scans.
Methods: We reviewed all patients who had DUS scans in 2012 at
our institution with nonvisualized calf veins, no deep vein thrombosis
(DVT), and available follow-up. Demographics, Well’s score, body mass in-
dex, reason for the DUS scan, activity level, reason for nonvisualization,
initial and subsequent DUS results, and subsequent occurrence of VTE
were collected.
Results: A total of 8237 DUS scans were performed in 2012. Of
these, 891 DUS scans (10.8%) in 717 patients had nonvisualized calf
veins. The study population comprised 484 of these patients who had
no DVT and had available follow-up. The most common reasons for
nonvisualization were edema (35.5%) and body habitus (31.8%). Ten
pulmonary emboli (PE) and 13 DVT comprising 23 VTE (4.8%)
were subsequently identiﬁed in the population. No tested variables
correlated with development of VTE. Of the 484 patients, 148 had a
subsequent DUS scan at a median of 2.43 months, and 45.3% of the
subsequent DUS scans successfully imaged the previously nonvisualized
veins. Lower body weight, whole leg swelling, single vein nonvisualiza-
tion, and single limb nonvisualization at the initial DUS scan were asso-
ciated with successful visualization on subsequent DUS scans. Thirteen
(8.8%) new DVTs were seen on subsequent DUS scans; six were seen in
